Filing Details

Accession Number:
0001818382-24-000166
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-08-29 18:48:06
Reporting Period:
2024-08-27
Accepted Time:
2024-08-29 18:48:06
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1818382 Humacyte Inc. HUMA Biological Products, (No Disgnostic Substances) (2836) 851763759
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1878075 E Laura Niklason 2525 East North Carolina Highway 54
Durham NC 27713
President, Ceo And Director Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2024-08-27 252,676 $6.71 4,306,464 No 4 S Indirect By Ayabudge LLC
Common Stock Disposition 2024-08-28 277,090 $6.47 4,029,374 No 4 S Indirect By Ayabudge LLC
Common Stock Disposition 2024-08-29 352,112 $6.35 3,677,262 No 4 S Indirect By Ayabudge LLC
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect By Ayabudge LLC
No 4 S Indirect By Ayabudge LLC
No 4 S Indirect By Ayabudge LLC
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 240,832 Direct
Common Stock 1,148,240 Indirect By The Niklason Living Trust
Common Stock 510,161 Indirect By spouse
Footnotes
  1. The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions.
  2. The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $6.58 to $7.075. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $6.36 to $6.60. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $6.13 to $6.56. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.